A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04222972 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

223

Enrollment

INDUSTRY

Sponsor class

Stopped Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

Conditions

RET-fusion Non Small Cell Lung Cancer
Lung Neoplasm
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Disease
Carcinoma, Bronchogenic
Bronchial Diseases
Head and Neck Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue

Interventions

DRUG: Pralsetinib
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Paclitaxel
DRUG: Nab-Paclitaxel

Sponsor

Hoffmann-La Roche